Uncomplicated gonorrhea in men was successfully treated with ceftriaxone in single intramuscular doses of 125 mg (15 patients), 250 mg (16 patients), or 500 mg (15 patients). All 45 pretreatment gonococcal isolates tested were inhibited by c0.016 yg of ceftriaxone per ml. Treatment was well tolerated and caused no toxicity.
The increasing prevalence of beta-lactamaseproducing strains of Neisseria gonorrhoeae (3, 7) and various disadvantages of the regimens recommended by the U.S. Centers for Disease Control (2) for gonorrhea due to beta-lactamasenegative strains have stimulated investigation of newly developed antimicrobial agents for the treatment ofuncomplicated gonorrhea. Ceftriaxone (Ro 13-9904) is a new cephalosporin that posesses unique pharmacokinetic properties, with a mean peak serum level of 93 ,ug/ml and a serum half-life of 8 h after a single intravenous dose of 500 mg (8) , and is one of the most active of all antibiotics against both beta-lactamasepositive and -negative N. gonorrhoeae (minimal inhibitory concentration [MIC] usually s0.008 ,ug/ml) (4-6, 9, 11) . These features suggest that ceftriaxone has potential value as a single-dose treatment for uncomplicated gonorrhea. We undertook a randomized dose-ranging study to assess the efficacy and tolerance of single intramuscular doses of 125, 250, or 500 mg of ceftriaxone in men with uncomplicated urethral or anorectal infection with beta-lactamase-negative N. gonorrhoeae.
Fifty-three men aged 216 years who attended a sexually transmitted disease clinic and who had presumptive gonococcal urethritis (urethral smear showing intracellular gram-negative diplococci) or anorectal infection (positive Gramstained smear or history of receptive rectal intercourse with a man with documented gonococcal urethritis) were enrolled in the study after giving written informed consent. Patients with histories of allergy to beta-lactam antibiotics, with complications of gonorrhea, or who had received antimicrobial therapy within the preceding 2 weeks were excluded. Ceftriaxone was dissolved in 1% lidocaine and administered in single intramuscular doses of 125 mg (0.5 ml), 250 mg (1.0 ml), or 500 mg (2.0 ml) according to a computer-generated randomization schedule provided by the manufacturer. Gonococcal infection was confirmed by the isolation of N. gonorrhoeae from 52 men, 46 6 were black, and 1 was Native American; 34 men were homosexual, and 12 were heterosexual. There were no significant differences in the distribution of these features among subjects assigned to the three doses of ceftriaxone. Table 1 shows the allocation of the three doses of ceftriaxone according to the anatomic sites that were infected. N. gonorrhoeae was eradicated from all infected sites of all 46 subjects, and all symptomatic patients had complete symptomatic resolution. No new sites were found to be infected at the follow-up visit. No significant hematological, urinary, or biochemical abnormalities occurred, except that anicteric viral hepatitis was documented before treatment in two men. In these cases, the hepatic function tests were unchanged or had returned toward normal at the follow-up visit. Table 2 shows the in vitro susceptibility of 45 strains of N. gonorrhoeae isolated in this study. The geometric mean MICs of ceftriaxone, pemcillin G, and tetracycline were 0.0043 ,ig/ml, 0.29 ,ug/ml, and 0.50 ,ug/ml, respectively. All isolates gave negative tests for beta-lactamase.
Ceftriaxone is a promising drug for single-dose treatment of uncomplicated gonorrhea. N. gonorrhoeae was eradicated from all infected sites, even with the 125-mg dose, and treatment caused no perceptible toxicity. The drug is readily soluble and could be injected through small- gauge needles; intramuscular injection of ceftriaxone in 1% lidocaine into the deltoid muscle was virtually painless. The in vitro susceptibility of N. gonorrhoeae to ceftriaxone in this study is consistent with that reported previously (4-6, 9, 11); moreover, beta-lactamase-producing strains have been reported (6, 11) to be as susceptible as beta-lactamase-negative strains. Thus, ceftriaxone in doses of 125 to 500 mg should be studied in controlled trials to compare its efficacy with that of established regimens for uncomplicated gonorrhea due to beta-lactamasepositive or -negative N. gonorrhoeae.
